Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well erlotinib works in treating participants with skin
squamous cell carcinoma that has spread to other places in the body or has come back. Drugs
used in chemotherapy, such as erlotinib, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) OSI Pharmaceuticals